Safety and efficacy of YM155 in diffuse large B-cell lymphoma (DLBCL)

被引：0
|
作者：
Cheson, B. D.
Vose, J. M.
Bartlett, N. L.
Lopez, A.
Van der Jagt, R. H.
Tolcher, A. W.
Weisenburger, D. D.
Seiz, A. L.
Shamsili, S.
Keating, A. T.
机构：
[1] Georgetown Univ Hosp, Bethesda, MD USA
[2] Univ Nebraska Med Ctr, Omaha, NE USA
[3] Washington Univ, Siteman Canc Ctr, St Louis, MO USA
[4] Hosp Valle De Hebron, Barcelona, Spain
[5] Ottawa Reg Canc Ctr, Ottawa, ON K1Y 4K7, Canada
[6] Inst Drug Dev, San Antonio, TX USA
[7] Astellas Pharma US Inc, Deerfield, IL USA
[8] Astellas Pharma Europe BV, Leiderdorp, Netherlands
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8502
引用
收藏
页数：2
相关论文
共 50 条
  • [1] A phase II study of the survivin suppressant YM155 in patients with refractory diffuse large B-cell lymphoma
    Cheson, Bruce D.
    Bartlett, Nancy L.
    Vose, Julie M.
    Lopez-Hernandez, Andres
    Seiz, Amanda L.
    Keating, Anne T.
    Shamsili, Setareh
    CANCER, 2012, 118 (12) : 3128 - 3134
  • [2] Tumor regression induced by YM155, a novel, survivin suppressant, in human diffuse large B-cell lymphoma models
    Kaneko, Naoki
    Kita, Aya
    Nakahara, Takahito
    Nakata, Mari
    Koutoku, Hiroshi
    Sasamata, Masao
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2010, 112 : 260P - 260P
  • [3] Diffuse large B-cell lymphoma (DLBCL)
    Renner, C.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2012, 82 : S10 - S10
  • [4] Combination of YM155, a survivin suppressant with a STAT3 inhibitor: A new strategy to treat diffuse large B-cell lymphoma
    Kaneko, Naoki
    Kita, Aya
    Yamanaka, Kentaro
    Mori, Masamichi
    LEUKEMIA RESEARCH, 2013, 37 (09) : 1156 - 1161
  • [5] Combination of YM155, a Survivin Suppressant, with Bendamustine and Rituximab: A New Combination Therapy to Treat Relapsed/Refractory Diffuse Large B-cell Lymphoma
    Kaneko, Naoki
    Mitsuoka, Keisuke
    Amino, Nobuaki
    Yamanaka, Kentaro
    Kita, Aya
    Mori, Masamichi
    Miyoshi, Sosuke
    Kuromitsu, Sadao
    CLINICAL CANCER RESEARCH, 2014, 20 (07) : 1814 - 1822
  • [6] A phase II study of the survivin suppressant YM155 in patients with refractory diffuse large B-cell lymphoma (vol 118, pg 3128, 2012)
    Cheson, Bruce D.
    Bartlett, Nancy L.
    Vose, Julie M.
    Lopez-Hernandez, Andres
    Seiz, Amanda L.
    Keating, Anne T.
    Shamsili, Setareh
    Papadopoulos, Kyriakos P.
    CANCER, 2012, 118 (17) : 4365 - 4365
  • [7] Effect of YM155, a potent survivin suppressant, on the antitumor effect of rituximab in diffuse large B-cell lymphoma (DLBCL) xenograft models: FLT-/FDG-PET imaging studies.
    Mitsuoka, K.
    Miyoshi, S.
    Kita, A.
    Yamanaka, K.
    Nakata, M.
    Murakami, Y.
    Noda, A.
    Jitsuoka, M.
    Fushiki, H.
    Nishimura, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [8] YM155, a Novel Survivin Suppressant, Improves the Antitumor Effect of Rituximab and Rituximab-Containing Regimens in Diffuse Large B Cell Lymphoma (DLBCL) Xenograft Mouse Models
    Nakata, Mari
    Nakahara, Takahito
    Kita, Aya
    Mitsuoka, Keisuke
    Yamanaka, Kentaro
    Kaneko, Naoki
    Miyoshi, Sosuke
    Mori, Masamichi
    Koutoku, Hiroshi
    Sasamata, Masao
    BLOOD, 2009, 114 (22) : 1064 - 1064
  • [9] Role of immunohistochemistry in staging diffuse large B-cell lymphoma (DLBCL)
    Talaulikar, D.
    Dahlstrom, J.
    Shadbolt, B.
    Broomfield, A.
    McDonald, A.
    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2008, 30 : 146 - 147
  • [10] The role of CNS prophylaxis in diffuse large B-cell lymphoma (DLBCL)
    Korfel, A.
    ONKOLOGIE, 2010, 33 : 26 - 27
12345